Status: Recruiting
Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma
This phase II trial tests the safety, side effects and effectiveness of mosunetuzumab in treating patients with slow growing (indolent) B-cell lymphoma. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread.
Participants needed: 20
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: University of WashingtonUpdated: Mar 13, 2026Locations: 1
Eligibility criteria
18 years or older at time of signing informed consent [+22]
History of severe allergic reaction to monoclonal antibody therapy [+11]